APOE and atherosclerosis: Liraglutide alone inhibited the progression of early onset, low-burden atherosclerotic disease (101) as well as attenuated pre-established atherosclerosis in ApoE -/- mice by reducing proinflammatory immune cells and mediators (102), suppressing foam cell formation (103) and lowering the endothelial expression of the proinflammatory vascular cell adhesion molecule 1 (104).